Alle Storys
Folgen
Keine Story von IsoTis OrthoBiologics mehr verpassen.

IsoTis OrthoBiologics

IsoTis to Release Second Quarter 2007 Results on August 7

Irvine, California (ots/PRNewswire)

IsoTis, Inc. (NASDQ: ISOT),
a leading orthobiologics company, will release its 2007 second
quarter results before opening of trading on Tuesday, August 7, 2007.
To discuss these results, the Company will conduct a conference
call at 4:00 p.m. (Eastern Time) / 1:00 p.m. (Pacific Time)/ 10:00
p.m. (Central European Time). Dial in details will be provided in the
Q2 2007 release on August 7, 2007.
About the company:
IsoTis is a leading orthobiologics company that develops,
manufactures and markets proprietary products for the treatment of
musculoskeletal diseases and disorders. IsoTis' current
orthobiologics products are bone graft substitutes that promote the
regeneration of bone and are used to repair natural, trauma-related
and surgically-created defects common in orthopedic procedures,
including spinal fusions. IsoTis' current commercial business is
highlighted by its Accell line of products, which the company
believes represents the next generation in bone graft substitution.

Contact:

For information contact: Rob Morocco, +1-949-855-7155,
robert.morocco@isotis.com; Hans Herklots, +1-949-855-7195 or
+41-21-620-6011, hans.herklots@isotis.com

Weitere Storys: IsoTis OrthoBiologics
Weitere Storys: IsoTis OrthoBiologics
  • 25.07.2007 – 14:09

    IsoTis SA to Delist From SWX, Euronext, and TSX on July 30, 2007

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company ("IsoTis"), today announced that it has concluded the squeeze-out merger of ISOTIS SA following an Extraordinary General Meeting of shareholders on July 23, 2007. As a result, ISOTIS SA has merged with and into IsoTis International SA, a wholly-owned subsidiary of IsoTis, and no longer exists as a separate legal entity. After ...

  • 18.06.2007 – 16:07

    IsoTis Expects Delisting From SWX, Euronext, and TSX in July 2007

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced that it is at the final stage of concluding the Exchange Offer it launched for all of the outstanding shares of ISOTIS SA on December 15, 2006. After this last step of the Exchange Offer, ISOTIS SA will no longer be listed on SWX Swiss Exchange, Euronext Amsterdam and the Toronto Stock Exchange. On ...

  • 30.05.2007 – 15:22

    IsoTis Regulatory Review of Accell Products Back on Track

    Irvine, California (ots/PRNewswire) - - FDA Reinitiates 510(k) Review IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced that it recently received a positive response from the Center for Biologics Evaluation and Research (CBER) and the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA), confirming that IsoTis' Accell family of demineralized ...